Course Description
Join our presentation to:
1.Meltzer et al., Validation
of a SNP-based Prenatal cell-free DNA screening for Fetal RhD Status in a Large
US Cohort, ACOG Annual Clinical and Scientific Meeting, May 2024, San
Francisco, CA.
Senior Medical Director,
Natera
Vivenne Souter, MD, MPH
Medical Director, Natera
Course expiration: July 29, 2026
Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk
Natera’s™ Fetal RhD noninvasive
prenatal testing (NIPT) is now available.
The test is backed by the largest clinical validation
study for fetal RhD in the US to date, and demonstrated
100% sensitivity, 99.3% specificity[1].
Speakers
Jeffrey T. Meltzer, MD,
MBA